Page 72 - Screening for Cervical Cancer: Systematic Evidence Review
P. 72

Chapter IV.  Discussion



               New Methods for Preparing or Evaluating Cervical Cytology



                       This portion of our SER evaluated the performance of new technologies for preparing or


               interpreting the cytology specimens;  these included liquid-based cytology collection systems,

               neural-net screening and rescreening tools, and computer algorithms for selecting slides for


               screening or rescreening.  This literature is fundamentally limited by lack of histologically

               confirmed performance measures—no gold standard is used for comparisons.  Of the very few


               studies using colposcopy and histology to verify the diagnostic test characteristics of new tools,

               the most common shortcoming was failure to apply the gold standard to test negative population

               or a subset to allow estimation of specificity.


                       To receive approval from the Food and Drug Administration, each of the new

                                                               
                                                     
                                                                              
               technologies currently in use (ThinPrep , PapNet , and AutoPap ) had to demonstrate improved
               sensitivity over conventional Pap testing.  As noted in the introduction of this chapter, improving

               sensitivity, especially if it amplifies detection of low-grade lesions, may not be a benefit at a


               population level in terms of reducing the burden of morbidity and mortality associated with

               cervical cancer.  This is especially true if increased sensitivity is accompanied by decreased


               specificity, requiring evaluation of a greater number of false positives and increasing costs.  It is

               precisely these parameters that are most poorly measured in this literature.


                       Overall, the quality of this literature is poor for the purposes of making decisions about

               choice of screening systems in US populations.  No randomized trials or prospective cohort


               studies relate use of a screening modality over time to outcomes for individual women.  The

               cost-effectiveness of use of new technologies has only been estimated, not measured directly.


               The most sophisticated and thorough cost model to date is significantly hindered by the

               limitations of the literature.  Nonetheless, it demonstrates that, at present, new technologies are




                                                             78
   67   68   69   70   71   72   73   74   75   76   77